Solvonis Therapeutics plc (LON:SVNS)
London · Delayed Price · Currency is GBP · Price in GBX 0.1150
-0.0050 (-4.17%)
Sep 4, 2026, 4:07 PM GMT
Solvonis Therapeutics Revenue
Revenue
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
6
Market Cap
7.83M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | 587.00K | 45.00K | 8.30% |
| Dec 31, 2022 | 542.00K | 166.57K | 44.37% |
| Dec 31, 2021 | 375.43K | -144.57K | -27.80% |
| May 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| May 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| May 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| May 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| IXICO | 7.28M |
| Fusion Antibodies | 1.60M |
| Aptamer Group | 1.38M |
| Oxford BioDynamics | 1.20M |
| OptiBiotix Health | 1.17M |
| Genflow Biosciences | 585.61K |
| CRISM Therapeutics | 231.00K |
| Thalia Therapeutics | 7.26K |